Sanofi (SNY) Depreciation & Amortization (CF) (2009 - 2026)

Sanofi has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting -$626.3 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 49.24% year-over-year to -$626.3 million; the TTM figure through Jun 2026 stood at -$2.7 billion (down 17.7% YoY), while the FY2025 annual figure was -$2.1 billion, down 268.14% from the prior year.
• Depreciation & Amortization (CF) came in at -$626.3 million for Q1 2026 at Sanofi, up from -$2.1 billion in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.6 billion in Q4 2023 to a low of -$2.1 billion in Q4 2025.
• Average Depreciation & Amortization (CF) over 5 years is -$64.6 million, with a median of $356.3 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) rose 0.28% in 2023 and slumped 217.79% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.6 billion in 2022, then increased by 0.28% to $1.6 billion in 2023, then sank by 215.11% to -$1.9 billion in 2024, then slipped by 10.61% to -$2.1 billion in 2025, then soared by 69.7% to -$626.3 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were -$626.3 million in Q1 2026, -$2.1 billion in Q4 2025, and -$419.7 million in Q1 2025.